Nicotine salts, co-crystals, and salt co-crystal complexes

Patent metadata

Field	Value
Publication number	US-2021122728-A1
Application number	US-202017094572-A
Country	US
Kind code	A1
Filing date	Nov 10, 2020
Priority date	May 27, 2014
Publication date	Apr 29, 2021
Grant date	—

Abstract

The invention provides certain nicotine salts, co-crystals, and salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, nicotine salts with orotic acid are described. The invention further provides methods of preparation and characterization of such nicotine salts. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided.

First claim

1 .- 20 . (canceled)

21 . An oral product comprising a salt of nicotine and fumaric acid, wherein the salt is a non-solvated mono-salt, characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 14.9, 18.4, 19.9, and 22.4.

22 . The oral product of claim 21 , in the form of loose moist snuff; loose dry snuff; chewing tobacco; pelletized tobacco pieces; extruded or formed tobacco strips, pieces, rods, cylinders or sticks; finely divided ground powders; finely divided or milled agglomerates of powdered pieces and components; flake-like pieces; molded tobacco pieces; gums; rolls of tape-like films; readily water-dissolvable or water-dispersible films or strips; meltable compositions; lozenges; pastilles; and capsule-like materials possessing an outer shell and an inner region.

23 . The oral product of claim 21 , in the form of a lozenge, wherein the lozenge further comprises at least about 50% by weight isomalt.

24 . The oral product of claim 21 , in the form of a lozenge, wherein the lozenge further comprises at least about 70% by weight isomalt.

25 . The oral product of claim 21 , in the form of a lozenge, wherein the lozenge further comprises at least about 80% by weight isomalt.

26 . The oral product of claim 23 , further comprising maltitol syrup.

27 . The oral product of claim 23 , further comprising one or more of a salt, sweetener, and flavoring.

28 . The oral product of claim 23 , wherein the salt is present in an amount of at least about 0.5% by weight of the product.

29 . The oral product of claim 21 , wherein at least about 50% of the salt is in crystalline form.

30 . The oral product of claim 21 , further comprising one or more components selected from the group consisting of excipients or carriers; thickeners, film formers, binders, antiadherents, glidants, humectants, preservatives, antioxidants, surfactants, dyes or pigments; lubricants or processing aids; salts; natural sweeteners; artificial sweeteners; pH adjusters or buffering agents; effervescing materials; oral care additives; syrups; lipids; and any combination of two or more such components.

31 . The oral product of claim 21 , further comprising one or more components selected from the group consisting of hydroxypropyl cellulose, microcrystalline cellulose, maltitol, gum arabic, sodium carbonate, sodium bicarbonate, sucralose, acesulfame K, flavorants, and any combination of two or more such components.

32 . The oral product of claim 21 , which does not contain a tobacco material.

33 . The oral product of claim 21 , further comprising a tobacco material.

34 . The oral product of claim 21 , wherein the salt of nicotine and fumaric acid comprises a majority of the nicotine in (R)-nicotine form.

35 . The oral product of claim 21 , wherein the salt of nicotine and fumaric acid comprises a majority of the nicotine in (S)-nicotine form.

36 . A method of preparing the oral product of claim 21 , comprising extruding, compressing, molding, or spraying a composition comprising the salt.

37 . A pharmaceutical product comprising a salt of nicotine and fumaric acid, wherein the salt is a non-solvated mono-salt, characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 14.9, 18.4, 19.9, and 22.4, and one or more pharmaceutically acceptable components.

38 . The pharmaceutical product of claim 37 , comprising a sufficient amount of the salt to provide nicotine in an amount effective to treat some symptoms of, or prevent occurrence of the symptoms of, a condition, disease, or disorder responsive to stimulation of one or more types of nicotine acetylchloinergic receptors (nAChRs) in a human subject.

39 . The pharmaceutical product of claim 38 , wherein the condition, disease, or disorder is selected from the group consisting of Alzheimer's disease, attention deficit disorder, schizophrenia, Parkinson's disease, Tourette's syndrome, ulcerative colitis, dry eye disease, hypertension, depression, overactive bladder, obesity, seven year itch/scabies, hemorrhoids, stress, pain, or any combination thereof.

40 . The pharmaceutical product of claim 37 , further comprising nicotine, where a total amount of nicotine in the product is an amount effective to treat some symptoms of, or prevent occurrence of the symptoms of, a condition, disease, or disorder responsive to stimulation of one or more types of nicotine acetylchloinergic receptors (nAChRs) in a human subject.

41 . The pharmaceutical product of claim 40 , wherein the condition, disease, or disorder is selected from the group consisting of Alzheimer's disease, attention deficit disorder, schizophrenia, Parkinson's disease, Tourette's syndrome, ulcerative colitis, dry eye disease, hypertension, depression, overactive bladder, obesity, seven year itch/scabies, hemorrhoids, stress, pain, or any combination thereof.

42 . The pharmaceutical product of claim 37 , in the form of a smoking cessation aid.

43 . The pharmaceutical product of claim 37 , in the form of a pill, tablet, lozenge, capsule, caplet, pouch, gum, cream, or liquid.

44 . The pharmaceutical product of claim 37 , wherein the one or more pharmaceutically acceptable components are selected from the group consisting of salts, sweeteners, fillers, flavorants, antiadherents, glidants, preservatives and antioxidants, surfactants, dyes or pigments, lubricants, processing aids, and combinations thereof.

45 . The pharmaceutical product of claim 37 , further comprising one or more components selected from the group consisting of hydroxypropyl cellulose, microcrystalline cellulose, maltitol, gum arabic, sodium carbonate, sodium bicarbonate, sucralose, acesulfame K, flavorants, and any combination of two or more such components.

46 . The pharmaceutical product of claim 37 , wherein the salt of nicotine and fumaric acid comprises a majority of the nicotine in (R)-nicotine form.

47 . The pharmaceutical product of claim 37 , wherein the salt of nicotine and fumaric acid comprises a majority of the nicotine in (S)-nicotine form.

Assignees

• Reynolds Tobacco Co R

Inventors

• Dull Gary M
• Carr Andrew
• Sharp Emma

Classifications

• A24F40/40

  Constructional details, e.g. connection of cartridges and battery parts · CPC title

• A61M2205/8206

  battery-operated · CPC title

• A61K9/0073

  Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M) · CPC title

• C07C57/15

  Fumaric acid · CPC title

• A24F40/20

  Devices using solid inhalable precursors · CPC title